Canine Patient Recruitment

As of June, 2018

If you would like additional information regarding a clinical trial, please contact us at:

Phone: (765) 496-9715
Fax: (765) 496-1108

If you believe your pet is eligible for a specific study, we recommend that you contact your veterinarian and request a referral. However, a referral may not be required to participate in some clinical trials.

To make an appointment at the Small Animal Hospital please call (765) 494-1107.


Canine Aggression Study in Labrador Retriever, Beagle and Standard Poodle

  • Description: This study is to compare genetic and behavior information between human directed aggressive dogs and non-aggressive (to both humans and animals) dogs in three different breeds to see if potential genetic and/or biomarkers may be identified.
  • Eligibility: Pure bred Labrador Retrievers, Beagles, or Standard Poodles that are either affected dogs (human aggressive dogs) or control dogs (no aggression toward humans or animals) are eligible.
  • Financial Incentive: No cost for collection of samples (blood). Blood collection can also be performed at the primary veterinarian office and shipped to us (cost for blood collection and shipping will be covered).
  • Primary Investigator: Dr. Niwako Ogata

For more information or to contact us

Behavioral and Physiological Responses in Dogs Under Social Anxiety

  • Description: A study to compare behavioral and physiological responses to identify the dogs at risk of social anxiety (both home and an exam room environment).
  • Eligibility: Clinically healthy dogs that must be neturered/spayed and between the ages of 1-13 years old can participate in the study.
  • Financial Incentive: No cost for collection of samples (saliva).
  • Primary Investigator: Dr. Niwako Ogata

For more information or to contact us


Atopic Dermatitis in Dogs

  • Description: The purpose of this study is to investigate the structure of the skin in dogs with atopic dermatitis. Skin biopsies and blood from dogs with atopic dermatitis and controls will be analyzed (immunofluorescence, RNA isolation, lipids and protein isolation). A better understanding of the disease may lead to new and improved treatments.
  • Eligibility: Any dog with clinically confirmed atopic dermatitis or a non-AD skin condition. Dogs must not have been treated with immunosuppressive or anti-inflammatory medication for at least two weeks.
  • Financial Incentive: There is no compensation for participation in this study; however, the biopsy and blood work are performed at no cost to you.
  • Primary Investigator: Dr. Paulo Gomes

Superficial Pyoderma in Dogs

  • Description: This study compares a novel animicrobial treatment to standard treatment of superficial pyoderma (skin infection) in dogs. Preliminary studies show that the new treatment is as good as or better than standard antibiotic treatment, and does not cause antibiotic resistance. Enrolled dogs are randomly assigned to standard treatment or the new treatment. The is to improve treatment for skin infections while decreasing the problem of antimicrobial resistance. 
  • Eligibility: Dogs with superficial pyoderma are eligible (baseline skin culture and swab are collected). Dogs with diarrhea, immune-mediated diseases, inflammatory bowel disease, or certain abnormal laboratory tests are excluded. 
  • Financial Incentive: There is no compensation for participation in the study. However, the costs of the skin culture and swab, other laboratory tests (CBC, serum chemistry, urinalysis), and the tested medications for the superficial pyoderma are covered by the study. Any diagnostic tests, treatments, or other veterinary care done outside of the PUVTH or any expense not related to this study must be paid for by the pet owner.
  • Primary Investigators: Drs. Paulo Gomes and Lynn Guptill

For more information or to contact us


MRI for Dogs Suspected to Have Brain Tumors

  • Description: A study to develop MRI in the diagnosis of dogs with brain tumors.
  • Eligibility: Any dog that is suspected to be suffering from a brain tumor. Examination by the Neurology & Neurosurgery service must confirm the suspicion of a brain tumor and eligibility for the study. Blood work and chest radiographs (from within the last month) must have already been performed – these may be performed at the referring veterinarian office before the appointment at Purdue.
  • Financial Incentive: The cost of the MRI is significantly reduced.
  • Primary Investigator: Dr. Timothy Bentley

Development of Novel Gait Clinical Outcome Measures in Normal Chondrodystrophic Breed Dogs

  • Purpose of study: To develop and validate novel body weight distribution, gait analysis and body composition protocols in a population of neurologically normal dogs. We are establishing normal values in a control population for subsequent comparison to dogs with spinal cord injury.
  • Eligibility: Any healthy adult, chondrodystrophic (Dachshunds, Corgis, French Bulldogs, Bassett Hounds, Pekingese, Shih Tzus, Cocker Spaniels, Beagles, etc) or chondrodystrophic mixed breed dog. Dogs must weigh less than 20 kgs (44 lbs), be between 1 and 10 years of age and have no history of confirmed or suspected spinal cord injury, orthopedic abnormalities or other health issues affecting mobility.
  • Financial Incentive: A physical exam and neurological exam, gait analysis, body weight distribution, body and limb circumference and hind limb joint angle scoring will be performed free of charge.
  • Primary Investigator: Dr. Melissa Lewis

For more information or to contact us


POOF Clinical Trial- (Piroxicam with Omeprazole Or Famotidine)

Dogs with Cancer Treated With Piroxicam

  • Description: A study to compare two commonly used gastroprotectants - famotidine and omeprazole – in dogs with cancer treated with piroxicam.
  • Eligibility: Any dog with a biopsy-confirmed diagnosis of cancer. Dogs with pre-existing kidney dysfunction or receiving gastroprotectants will not be enrolled.  A 2-week washout period is required for dogs treated with radiation therapy, chemotherapy, or a different non-steroidal anti-inflammatory drug (NSAID).
  • Financial Incentive: Office visits and labwork will be eligible for a research discount.  An additional incentive of approximately $65 per visit will be provided.
  • Primary Investigator: Drs. Christopher Fulkerson and Marejka Shaevitz

Vemurafenib Treatment in Dogs with Bladder Cancer, i.e. Transitional Cell Carcinoma (TCC)

  • Description: The purpose of this study is to determine the anti-tumor effects, the toxicity (or lack thereof), and the appropriate dose of Vemurafenib in dogs with TCC.  Vemurafenib is a drug that kills tumor cells that have a very precise mutation. The goal is to improve the outlook for pet dogs and people with cancer. 
  • Eligibility
    • Biopsy proof of TCC
    • Confirmed BRAF V600E mutation in TCC cells in the urine (a urine test)
    • Measurable cancer lesions that can be followed to assess antitumor effects
    • Acceptable “performance status” (the dogs still feels OK)
    • Expected survival ≥ 6  weeks
    • Acceptable kidney function (serum creatinine ≤ 2mg/dl)
  • Financial Incentive: The pet owner is required to pay $250.00 per month for the expenses incurred in the Purdue University Veterinary Teaching Hospital (PUVTH) related to the treatment and monitoring. The funding agency will cover the remainder of the cost related to the Vemurafenib treatment and monitoring in the PUVTH. Any work done outside of the PUVTH or any expenses not related to the Vemurafenib treatment must be paid by the pet owner. 
  • Primary Investigator: Dr. Deborah Knapp

For more information or to contact us


Golden Retriever Pigmentary Uveitis (PU)

  • Description: A study to better understand the disease progression of PU and establish a DNA bank of samples from both affected and normal Golden Retrievers.
  • Eligibility: Any purebred Golden Retriever.
  • Financial Incentive: There is no compensation for participation in this study. However, the ocular examination is performed at no cost to you.
  • Primary Investigator: Dr. Wendy Townsend

For more information or to contact us


Polyarthritis – Folate-receptor Targeted Drug Delivery

  • Description: A study to evaluate a new folate-receptor drug complex for the treatment of immune mediated polyarthritis in dogs. The drug has strong anti-inflammatory activity, similar to the new rheumatoid arthritis drugs for humans.
  • Eligibility: Dogs with naturally occurring immune mediated polyarthritis.
  • Financial Incentive: All costs related to the diagnosis and rechecks through the 16 week recheck will be reimbursed to the owner. The owner is responsible for the cost of the initial visit for diagnosis. During this visit, the scintigraphy will be done free of charge. Once the diagnosis of immune mediated polyarthritis is made, the owner will be advised about eligibility for enrollment.
  • Primary Investigator: Dr. Gert Breur

For more information or to contact us

    Purdue University College of Veterinary Medicine, 625 Harrison Street, West Lafayette, IN 47907, (765) 494-7607

    © 2018 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by PVM Web Communications

    If you have trouble accessing this page because of a disability, please contact PVM Web Communications at